## Abstract Mass spectrometry (MS)‐based proteomics is a rapidly developing technology for both qualitative and quantitative analyses of proteins, and investigations into protein posttranslational modifications, subcellular localization, and interactions. Recent advancements in MS have made tremend
Protein biomarker discovery for head and neck cancer
✍ Scribed by Tieneke B.M. Schaaij-Visser; Ruud H. Brakenhoff; C. René Leemans; Albert J.R. Heck; Monique Slijper
- Publisher
- Elsevier
- Year
- 2010
- Tongue
- English
- Weight
- 580 KB
- Volume
- 73
- Category
- Article
- ISSN
- 1874-3919
No coin nor oath required. For personal study only.
✦ Synopsis
Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer worldwide. Despite improvements in diagnosis and treatment, the five-year-survival rate of advanced HNSCC has only moderately increased, which is largely due to the high proportion of patients that present with advanced disease stage and the frequent development of relapse and second primary tumors. Protein biomarkers allowing early detection of primary HNSCC or relapse may aid to improve clinical outcome. Screening for precursor changes in the mucosal linings preceding the development of invasive tumors and for accurate prediction of risk of malignant transformation, may be propitious opportunities, which are as yet difficult. This review summarizes recent results in HNSCC proteomics for biomarker research. Despite the wide diversity of experimental designs, a few common markers have been detected. Although some of these potential biomarkers are very promising, they still have to be further clinically validated. Finally, treatment of advanced cancers of several sites within the head and neck has shifted significantly during the last decade, and also, targeted drugs have entered the clinic. This has major consequences for the research questions in HNSCC research and accordingly for the future direction of proteome research in HNSCC biomarker discovery.
📜 SIMILAR VOLUMES
## Abstract ## Objectives/Hypothesis: Serum protein profiling by SELDI‐TOF‐MS distinguishes pretreatment and post‐treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease‐free or recurrence) with a high degree of sensitivity and specificity. We sou